Skip to main content
ARCT logo

ARCT · Arcturus Therapeutics Holdings Inc. · Webcasts, Transcripts & Audio

Track ARCT — free
$7.45 -0.15 (-1.97%) At close · Nov 20 Play latest call Q3 2026 earnings call transcript
Market Cap
$214.73M
Shares
28.82M
Volume · Nov 20 602K Avg daily vol (3M) 883.08K

Arcturus Therapeutics Holdings Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Arcturus Therapeutics Holdings Inc. (ARCT), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Conference
Investor event
2026-11-09
Arcturus Therapeutics Holdings Inc. (ARCT) November 9, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q3
2026-11-05
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2026 Earnings Call Transcript
Confident tone Development and regulatory timing risks OTC deficiency programs Lunar 2.0 delivery platform
Revenue
$18.30M
▲ 6.7% YoY
Diluted EPS
$-0.26
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Investor Update
Investor event
2026-09-23
Arcturus Therapeutics Holdings Inc. (ARCT) September 23, 2026 Investor Update Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-09
Arcturus Therapeutics Holdings Inc. (ARCT) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-08-11
Arcturus Therapeutics Holdings Inc. (ARCT) August 11, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-08-11
Arcturus Therapeutics Holdings Inc. (ARCT) August 11, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-06
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call
Revenue
$2.96M
▼ 89.5% YoY
Diluted EPS
$-0.84
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 Earnings Call Transcript
Positive tone OTC Deficiency / ARCT-810 Program Cystic Fibrosis / ARCT-032 Program Regulatory Progress with FDA
Revenue
$2.06M
▼ 93% YoY
Diluted EPS
$-0.95
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-03
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2025 Earnings Call Transcript
Positive tone ARCT-032 cystic fibrosis Phase II ARCT-810 OTC deficiency development STARR sa-mRNA platform validation
Revenue
$7.20M*
▼ 68.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-10
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2025 Earnings Call Transcript
Positive tone Clinical Trial Enrollment Expansion ARCT032 Cystic Fibrosis Program Costave COVID-19 Vaccine
Revenue
$17.15M
▼ 58.8% YoY
Diluted EPS
$-0.49
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-11
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2025 Earnings Call Transcript
Positive tone ARCT-032 Cystic Fibrosis program FDA regulatory alignment and Phase III planning ARCT-810 OTC deficiency program
Revenue
$28.30M
▼ 43.2% YoY
Diluted EPS
$-0.34
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2025 Earnings Call Transcript
Positive tone ARCT-810 OTC deficiency program KOSTAIVE COVID-19 vaccine commercialization ARCT-032 Cystic Fibrosis Phase 2
Revenue
$29.38M
▼ 22.7% YoY
Diluted EPS
$-0.52
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-06
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2024 Earnings Call Transcript
Positive tone Meiji KOSTAIVE Sales Shortfall ARCT-032 Cystic Fibrosis Program KOSTAIVE Vaccine Approvals and Commercialization
Revenue
$22.77M*
▼ 26.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2024 Earnings Call Transcript
Confident tone KOSTAIVE commercial launch in Japan Arcalis manufacturing strategic asset ARCT-032 cystic fibrosis program
Revenue
$41.67M
▼ 7.7% YoY
Diluted EPS
$-0.26
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-05
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2024 Earnings Call Transcript
Confident tone ARCT-810 OTC deficiency program ARCT-032 cystic fibrosis therapeutic Kostaive COVID-19 vaccine launch and regulatory progress
Revenue
$49.86M
▲ 374% YoY
Diluted EPS
$-0.64
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2024 Earnings Call Transcript
Confident tone Kostaive COVID-19 vaccine commercialization in Japan ARCALIS joint venture monetization ARCT-032 cystic fibrosis inhaled mRNA program
Revenue
$38.01M
▼ 52.7% YoY
Diluted EPS
$-1.00
▼ 153.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-07
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2023 Earnings Call Transcript
Confident tone Kostaive COVID-19 Vaccine Approval and Launch Manufacturing and Partnerships (CSL, Meiji, ARCALIS) Regulatory Strategy and Geographic Expansion
Revenue
$30.86M*
▼ 80.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-14
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2023 Earnings Call Transcript
Revenue
$45.14M
▲ 237.6% YoY
Diluted EPS
$-0.61
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2023 Earnings Call Transcript
Revenue
$10.52M
▼ 61.2% YoY
Diluted EPS
$-1.98
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2023 Earnings Call Transcript
Revenue
$80.28M
▲ 1431% YoY
Diluted EPS
$1.87
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-28
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2022 Earnings Call Transcript
Revenue
$160.29M*
▲ 2666.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2022 Earnings Call Transcript
Revenue
$13.37M
▲ 448.6% YoY
Diluted EPS
$-1.33
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2022 Earnings Call Transcript
Revenue
$27.09M
▲ 1254% YoY
Diluted EPS
$-0.82
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2022 Earnings Call Transcript
Revenue
$5.24M
▲ 146.5% YoY
Diluted EPS
$-1.94
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2021 Earnings Call Transcript
Revenue
$5.79M
▲ 158.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-08
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2021 Earnings Call Transcript
Revenue
$2.44M
▲ 4.5% YoY
Diluted EPS
$-2.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2021 Earnings Call Transcript
Revenue
$2.00M
▼ 13.8% YoY
Diluted EPS
$-2.07
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2021 Earnings Call Transcript
Revenue
$2.13M
▼ 19.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-01
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2020 Earnings Call Transcript
Revenue
$2.24M
▼ 24.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-09
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2020 Earnings Call Transcript
Revenue
$2.33M
▼ 29.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2020 Earnings Call Transcript
Revenue
$2.32M
▼ 77.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2020 Earnings Call Transcript
Revenue
$2.65M
▼ 39.2% YoY
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-11
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2019 Earnings Call
Revenue
$2.97M
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–33 of 33 webcasts
Key facts CIK 1768224 CUSIP 03969T109 13F (30d) 172 filings 143 filers Visit website Investor relations